Novartis created a chemotherapy drug called Tasigna in 2002. The FDA later approved it in 2007. Tasigna is most commonly used to treat chronic myeloid leukemia (CML) in its more advanced stages. The drug has proven to be more effective than other chemotherapy drugs, but it has more side effects, some of which are more deadly.